IMNM
Immunome Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.21
−0.44%Oct 30, 2026, 11:30 UTC
Immunome announced that the EUROPEAN MEDICINES AGENCY validated its marketing authorization application for varegacestat to treat adults with desmoid tumors.
Source:Oct 26, 2026, 11:00 UTC
Immunome announced that additional clinical data for investigational varegacestat in desmoid tumors were presented in four presentations at the 2026 ESMO Congress.
Source:Oct 6, 2026, 20:02 UTC
Immunome granted inducement awards consisting of options to purchase 120,900 shares of common stock and 7,200 restricted stock units.
Source:Oct 5, 2026, 12:31 UTC
Immunome Inc. amended its license agreement with Bristol-Myers Squibb, paying $20.0 million in cash and issuing 4,425,487 shares of common stock to acquire patent rights related to varegacestat and AL101 and remove milestone and royalty obligations.
Sep 30, 2026, 11:45 UTC
The U.S. FDA cleared Immunome's Investigational New Drug application for IM-1340, a first-in-class antibody-drug conjugate for advanced solid tumors.
Source:Jul 20, 2026, 11:30 UTC
Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.
Source:Jul 8, 2026, 11:30 UTC
Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.